The highly specific binding of KMP1 to CD44 may be due to O‐linked glycosylation of CD44 mediated by ppGalNAc T1, suggesting that KMP1 will probably be a potential specific therapeutic activity and diagnostic biomarker or targeted agent for bladder cancer. This evidence concerns the gene CD44 and urinary bladder cancer.